Straits Financial Services Pte Ltd Granted Overseas Intermediary Futures Broker Status by Shanghai Futures Exchange and Guangzhou Futures Exchange

Straits Financial Services Pte Ltd Granted Overseas Intermediary Futures Broker Status by Shanghai Futures Exchange and Guangzhou Futures Exchange

SINGAPORE, April 27, 2026 /PRNewswire/ -- Straits Financial Services Pte Ltd ("SFSPL"), a member of Straits Financial Group, is pleased to announce that it has been granted overseas intermediary (OI) futures broker status by the Shanghai Futures...

Singtel Receives Frost & Sullivan's 2025 Asia-Pacific Enabling Technology Leadership Recognition for Advancing 5G and Multi-Infrastructure AI Orchestration

Singtel Receives Frost & Sullivan's 2025 Asia-Pacific Enabling Technology Leadership Recognition for Advancing 5G and Multi-Infrastructure AI Orchestration

Singtel is recognized for driving transformative innovation in 5G, AI orchestration, and digital infrastructure excellence across Asia-Pacific. SAN ANTONIO, Dec. 16, 2025 /PRNewswire/ -- Frost & Sullivan is pleased to announce that Singtel has...

HiroPharmaConsulting (R) Granted Patent for AI-enabled Reliability Assurance Method for Pharmacovigilance Systems

HiroPharmaConsulting (R) Granted Patent for AI-enabled Reliability Assurance Method for Pharmacovigilance Systems

OSAKA, Japan, Dec. 4, 2025 /PRNewswire/ -- HiroPharmaConsulting (R) Co., Ltd. announced that it has received a patent for an innovative Good Pharmacovigilance Practice (GVP) Computerized System Validation (CSV) methodology designed to ensure the...

Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer

Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer

CHENGDU, China, June 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱®) in combination with the...

menu
menu